News & Updates

Amivantamab plus chemotherapy with or without lazertinib results in longer progression-free survival (PFS), as well as intracranial PFS, compared with chemotherapy alone in patients with epidermal growth factor receptor (EGFR)-mutated advanced nonsmall-cell lung cancer (NSCLC) who had disease progression on or after osimertinib, results of the phase III MARIPOSA-2 study have shown.

The addition of internal mammary nodal irradiation (IMNI) in the treatment of breast cancer leads to better overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and lower breast cancer mortality (BCM), reveals a study. In addition, patients with pN+ and medial/central tumour location achieved the best OS from IMNI.

A 52-week course of intensified androgen-deprivation therapy (ADT) appears to extend prostate-specific antigen progression-free survival (PSA-PFS) in patients with biochemically recurrent prostate cancer (BRPC) compared with ADT alone, without prolonging time to testosterone recovery, according to the phase III open-label PRESTO trial.

Noncontrast-enhanced magnetic resonance imaging (NCEMRI) demonstrates superiority over ultrasonography (US) for the surveillance of hepatocellular carcinoma (HCC) in at-risk populations, although this strategy is more expensive than US, according to a Singapore study.

Patient use of self-adjusted nitrous oxide (N2O) at levels of 20 percent to 45 percent during transrectal prostate biopsy is safe and well tolerated, according to a study. Delivery of low-dose N2O is associated with reduced pain, but its effect on anxiety does not seem significant.

Therapeutic drug monitoring (TDM) helps identify children treated by thiopurine for acute lymphoblastic leukaemia (ALL) and inflammatory bowel disease (IBD) who have not reached their target levels or are over treated, reports a recent study.